Table 1.

Anti-VEGF agents and related incidence of arterial hypertension

Anti-VEGF agent	Therapeutic target	Incidence of arterial hypertension
Bevacizumab	VEGF ligand	22–24%
Sunitinib	VEGFR, PDGFR, KIT, FLT3, CSR, RET	15–34%
Sorafenib	VEGFR, PDGFR, KIT, FLT3, RET	17–29%
Axitinib	VEGFR	40%
Pazopanib	VEGFR, PDGFR, FGFR, KIT, Itk, Lck, c-FMS	36–46%
Ponatinib	VEGFR, PDGFR, FGFR, EPH, BCR-ABL, KIT, FLT3, RET, Src, TIE2	67%
Regorafenib	VEGFR, PDGFR, FGFR, KIT, RET, BRAF	28–48%
Cabozantinib	VEGFR, KIT, FLT3, RET, MET, TRKB, AXL, TIE2	32–37%
Vandetanib	VEGFR, EGFR, RET	24%